Join us for Ohio State’s Scarlet and Gray Reception during the AACR Annual Meeting.
Saturday, April 26
6:30-8:30 p.m.
Hilton Chicago, Buckingham Room
720 South Michigan Avenue
Chicago, Illinois 60605
Fellow of the AACR Academy
Electra Paskett, PhD, MSPH, FACE
Deputy Director for Population sciences and Community Outreach
Director of the Center for Community Outreach and Engagement
OSUCCC – James
The mission of the Fellows of the AACR Academy is to recognize and honor extraordinary scientists whose groundbreaking contributions have driven significant innovation and progress in the fight against cancer. Fellows of the AACR Academy constitute a global brain trust of leading experts in cancer science and medicine, working to advance the AACR’s mission to prevent and cure all cancers through research, education, collaboration, communication, advocacy, and funding for cancer research.
Presentations and sessions by OSUCCC – James experts at AACR
Learn more about specific presentations and sessions by OSUCCC – James experts at the American Association for Cancer Research® (AACR) Annual Meeting 2025.
Poster Sessions
Monday, April 28, 9 a.m. – 12 p.m.
Author: Christian Showalter, PhD
Session Title: Radiation Sciences 1
Poster#: 4
Title: Deciphering PSMA7 modulation by RT and TMZ for enhanced GBM treatments
Author: Ganesh Yadaigiri
Session Title: Novel Antitumor Agents 1
Poster#: 24
Title: A novel small molecule inhibitor, HO-4200, modulates macrophage polarization and suppresses MDSCs to enhance antitumor immune responses in ovarian cancer
Monday, April 28, 2 – 5 p.m.
Author: Merve Hasanov, MD
Session Title: Prognostic Biomarkers 2
Poster#: 14
Title: The 31-gene expression profile identifies patients at risk of developing early distant metastases and can guide risk-appropriate surveillance strategies
Author: Marisa Bittoni, PhD, MS
Session Title: The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum
Poster#: 5
Title: The BE FIT study: feasibility of an exercise intervention on the microbiome and immune function in a high-risk cohort for lung cancer
Author: Faiza Kalam, PhD
Session Title: The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum
Poster#: 4
Title: Extracellular vesicle dynamics in alternate-day fasting combined with low-carbohydrate weight loss intervention
Tuesday, April 29, 9 a.m. – 12 p.m.
Author: Min-Ae Song
Session Title: Late-Breaking Research: Molecular/Cellular Biology and Genetics 2
Poster#: 4
Title: Epigenetic age in normal breast tissues and its association with breast cancer risk factors
Author: Asrar Alahmadi
Session Title: Phase I Clinical Trials in Progress 2
Poster#: 16
Title: An open-label phase 1 study to investigate JBZ001 in adults with advanced solid tumors and non-Hodjkin lymphoma (JBZ001, Trial in Progress)
Author: Gautam Sarathy
Session Title: Regulation of Gene Expression in Drug Resistance
Poster#: 6
Title: Enhancing chemotherapeutic activity against triple-negative breast cancer cells using induced electric fields
Author: Federica Calore, PhD
Session Title: Late-Breaking Research: Clinical Research 2 / Endocrinology
Poster#: 13
Title: Evaluating TRAP1 as a novel, potential therapeutic target in dedifferentiated liposarcoma
Tuesday, April 29, 2 – 5 p.m.
Author: Cuthbert Mahenge, MD, MPH
Session Title: Health Disparities and Systemic Inequities: Lifestyle, Metabolism, and Disparities in Cancer Risk and Outcomes
Poster#: 13
Title: Impact of body composition on tumor proteomics and survival outcomes in clear cell renal cell carcinoma
Author: Holli Loomans-Kropp, PhD
Session Title: Development of Chemopreventive Agents and Preclinical Models
Poster#: 9
Title: Metformin induces cell cycle arrest and inhibits proliferation in KRAS-mutated colorectal cancer
Wednesday, April 30, 9 a.m – 12 p.m.
Author: Rand Lucine Akasheh, PhD
Session Title: Socioeconomic, Lifestyle, and Biological Drivers of Cancer Risk and Survival: Clinical Outcomes and Treatment Guidelines
Poster#: 2
Title: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review
Author: Holli Loomans-Kropp, PhD
Session Title: Innovations in Prevention and Cancer Care: Addressing Disparities, Inflammation, Survivorship, and Modifiable Risk Factors
Poster#: 17
Title: Systemic chronic inflammation is associated with quality of life in the Cancer Disparities Research Network
Featured news story
Ohio State drug discovery enters clinical testing, secures commercialization partner
A new therapeutic agent developed at The Ohio State University will be used for cancer treatment in a clinical trial. The trial, led by the OSUCCC – James, will test a best-in-class DHODH inhibitor discovered and developed at Ohio State.
Featured Experts
Electra Paskett, PhD, MSPH, FACE
Deputy Director, Population Sciences and Community Outreach
Director, Center for Community Outreach and Engagement
Chyke A Doubeni, MBBS, MPH
Associate Director,
The Ohio State University Comprehensive Cancer Center
Clinical Trials
The OSUCCC – James is one of only a few comprehensive cancer centers funded by the National Cancer Institute (NCI) to conduct phase I and phase II clinical trials on novel anticancer drugs.
Follow the OSUCCC – James on social media
#AACR2025, Facebook @OSUCCCJames, Twitter @OSUCCC_James, and LinkedIn.